Diroximel
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications
Cost-effectiveness of cladribine tablets for the treatment of active relapsing-remitting multiple sclerosis in the United Kingdom.
Journal: Current medical research and opinion
Published: October 22, 2026
Structure-Property Relationship Analysis of α-Keto Ester Prodrugs of Monomethyl Fumarate as NRF2 Activators.
Journal: ACS chemical neuroscience
Published: July 07, 2026
Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis.
Journal: Clinical immunology (Orlando, Fla.)
Published: July 07, 2026
Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation.
Journal: PloS one
Published: April 11, 2026
Predictors of high- versus low-intensity first-line multiple sclerosis treatments.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: February 19, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes.
Journal: Advances in therapy
Published: February 13, 2026
Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Multiple sclerosis and related disorders
Published: December 12, 2025
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.
Journal: Advances in therapy
Published: October 23, 2025
Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study.
Journal: International journal of molecular sciences
Published: October 16, 2025
Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.
Journal: Neurodegenerative disease management
Published: October 07, 2025
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: September 12, 2025
Effect of diroximel fumarate on gut dysbiosis and autoimmunity in the central nervous system.
Journal: International immunopharmacology
Published: August 22, 2025
Last Updated: 11/08/2026